子宮頸癌診斷市場規模 - 按診斷方法、年齡層、最終用途和預測，2024-2032 年

由於人們越來越意識到子宮頸癌早期檢測和篩檢計畫的重要性，預計從 2024 年到 2032 年，子宮頸癌診斷市場規模將以超過 5.3% 的CAGR擴大。 HPV 檢測和液基細胞學等診斷技術的持續發展正在提高子宮頸癌診斷的準確性和效率。

全球子宮頸癌發生率不斷上升，特別是在發展中地區，增加了對診斷的需求。根據美國癌症協會預測，到 2024 年，美國將診斷出 13,820 例新的侵襲性子宮頸癌病例。多個政府也正在發起計劃和醫療保健活動，以促進子宮頸癌篩檢和預防。

2023 年 9 月，國際癌症研究機構 (IARC) 及其合作夥伴的科學家啟動了 EASTER 項目，旨在驗證子宮頸癌篩檢和診斷的新技術。此類開發子宮頸癌診斷新技術的項目的啟動將為市場發展提供動力。

子宮頸癌診斷產業分為診斷方法、年齡層、最終用途和地區。

根據診斷方法，由於子宮頸癌診斷的廣泛採用，HPV DNA 檢測的市場價值預計到 2032 年將以 5.6% 的CAGR成長。這些檢測在檢測人類乳突病毒 (HPV) 感染（子宮頸癌的主要原因）方面具有高靈敏度和特異性。 HPV DNA 檢測還可以進行早期檢測和干涉，以改善患者的治療結果，進一步推動全球子宮頸癌篩檢計畫的使用率不斷提高。

就最終用途而言，診斷影像中心預計將在子宮頸癌診斷市場中累積相當大的佔有率，2024年至2032年的CAGR為4.9%。這是由於人們越來越認知到定期子宮頸癌篩檢的重要性。最近，專門中心已經高度可用先進的診斷影像技術。這些中心提供子宮頸癌檢測的專業服務，透過陰道鏡、MRI 和超音波等技術提供準確、及時的診斷，有助於改善患者的治療效果。

從地區來看，由於醫療保健支出不斷增加、宣傳活動不斷加強以及政府改善女性健康舉措的推出，亞太地區子宮頸癌診斷市場規模從 2024 年到 2032 年將以 5.6% 的速度成長。中國和印度等新興經濟體醫療基礎設施的快速發展，以及篩檢計畫的日益普及，將推動區域產業的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 全球子宮頸癌盛行率上升
    • 政府和其他組織為傳播疾病意識而採取的多項舉措
    • HPV 感染發生率上升
    • 診斷技術的進步
  • 產業陷阱與挑戰
    • 獲得醫療服務的機會有限
    • 社會恥辱與文化障礙
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 戰略儀表板

第 5 章：市場估計與預測：透過診斷方法，2018 - 2032

• 主要趨勢
• 子宮頸抹片檢查
• HPV DNA 檢測
• 陰道鏡檢查
• 活體組織切片和子宮頸內刮除術
• 其他診斷方法

第 6 章：市場估計與預測：按年齡分類，2018 - 2032

• 主要趨勢
• 20-40歲
• 40歲以上

第 7 章：市場估計與預測：按最終用途，2018 - 2032 年

• 主要趨勢
• 醫院
• 診斷實驗室
• 診斷影像中心
• 癌症研究機構
• 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• Arbor Vita Corporation
• Becton, Dickinson and Company (BD)
• Danaher Corporation
• F. Hoffmann-La Roche Ltd
• Fujirebio Diagnostics, Inc.
• Hologic, Inc.
• QIAGEN
• Seegene Inc
• Thermo Fisher Scientific Inc.

Cervical Cancer Diagnostics Market size is estimated to expand at over 5.3% CAGR from 2024 to 2032, on account of the increasing awareness about the importance of early detection and screening programs for cervical cancer. Rising developments in diagnostic techniques like HPV testing and liquid-based cytology are improving the accuracy and efficiency of cervical cancer diagnosis.

The rising incidences of cervical cancer globally, especially in developing regions, are increasing the demand for diagnostics. As per the American Cancer Society, in 2024, 13,820 new cases of invasive cervical cancer will be diagnosed in the U.S. Several governments are also launching initiatives and healthcare campaigns to promote cervical cancer screening and prevention.

In September 2023, scientists at the International Agency for Research on Cancer (IARC) and its partners launched the EASTER project, aimed at validating new technologies for cervical cancer screening and diagnosis. The launch of such projects to develop new technologies for cervical cancer diagnosis will provide impetus for the market development.

The cervical cancer diagnostics industry is bifurcated into diagnostic method, age group, end-use, and region.

Based on diagnostic method, the market value from the HPV DNA tests is anticipated to rise at 5.6% CAGR up to 2032, due to the high adoption for cervical cancer diagnosis. These tests offer high sensitivity and specificity in detecting human papillomavirus (HPV) infections, a leading cause of cervical cancer. HPV DNA tests also enable early detection and intervention for improved patient outcomes, further driving increasing utilization in cervical cancer screening programs worldwide.

In terms of end-use, the diagnostic imaging centers segment is estimated to accumulate sizeable share of the cervical cancer diagnostics market, depicting 4.9% CAGR from 2024 to2032. This is owing to the increasing awareness about the importance of regular cervical cancer screening. Of late, there has been high availability of advanced diagnostic imaging technologies in dedicated centers. These centers provide specialized services for cervical cancer detection for offering accurate and timely diagnosis through techniques such as colposcopy, MRI, and ultrasound, contributing to improved patient outcomes.

Regionally, the Asia Pacific cervical cancer diagnostics market size will depict 5.6% growth rate from 2024 to 2032, owing to the rising healthcare expenditure, increasing awareness campaigns, and rollout of government initiatives to improve women health. Rapid advancements in healthcare infrastructure in emerging economies like China and India, along with the growing adoption of screening programs will fuel the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cervical cancer globally
    • 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
    • 3.2.1.3 Rising incidence of HPV Infections
    • 3.2.1.4 Advancements in diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited access to healthcare services
    • 3.2.2.2 Social stigma and cultural barriers
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Diagnostic Methods, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Pap smear tests
• 5.3 HPV DNA tests
• 5.4 Colposcopy
• 5.5 Biopsy and endocervical curettage
• 5.6 Other diagnostic methods

Chapter 6 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 20-40 years
• 6.3 Above 40 years

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Diagnostic imaging centers
• 7.5 Cancer research institutes
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Arbor Vita Corporation
• 9.3 Becton, Dickinson and Company (BD)
• 9.4 Danaher Corporation
• 9.5 F. Hoffmann-La Roche Ltd
• 9.6 Fujirebio Diagnostics, Inc.
• 9.7 Hologic, Inc.
• 9.8 QIAGEN
• 9.9 Seegene Inc
• 9.10 Thermo Fisher Scientific Inc.